ClinicalTrials.gg
Not yet recruitingNCT07948252Updated Nov 19, 2026

Phrenic Nerve-Guided Interscalene Block: Diaphragm Paralysis and Analgesia

An interventional study of Ultrasound-Guided Intrafascial Injection (10 ml) and Ultrasound-Guided Extrafascial Injection (10 ml) in Diaphragmatic Paralysis, Shoulder Surgery and Postoperative Pain, sponsored by Ankara Etlik City Hospital. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Ankara Etlik City Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The primary objective of this prospective clinical study is to evaluate the incidence of hemidiaphragmatic paralysis when the phrenic nerve is utilized as a primary sonographic landmark during interscalene brachial plexus blocks. While interscalene blocks provide excellent analgesia for shoulder surgeries, they are frequently associated with unintended phrenic nerve blockade, leading to diaphragmatic paresis or paralysis. This study hypothesizes that utilizing the phrenic nerve as a specific landmark to guide local anesthetic injection will [reduce] the frequency of diaphragmatic paralysis while maintaining adequate surgical anesthesia.

02

Conditions studied

  • Diaphragmatic Paralysis
  • Shoulder Surgery
  • Postoperative Pain

Keywords

  • Interscalene Block
  • Phrenic Nerve
  • Ultrasound-Guided Regional Anesthesia
  • Hemidiaphragmatic Paresis
  • Shoulder Arthroscopy
  • Postoperative Analgesia
03

In context

Respiratory Paralysis

37 studies on the registry are indexed under Respiratory Paralysis; 9 are open to participants now.

This study's planned enrollment of 50 is close to the median of 48 across 20 interventional studies indexed under Respiratory Paralysis.

Browse Respiratory Paralysis studies →

Lead sponsor

Ankara Etlik City Hospital is the lead sponsor of 180 studies on the registry; 78 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged between 18 and 75 years.
  • (ASA) physical status I, II, or III.
  • Scheduled for elective arthroscopic shoulder surgery.
  • Patients who are informed about the study and provide written .

Exclusion criteria

Exclusion Criteria:

  • Known allergy to local anesthetics.
  • Presence of infection at the application/injection site.
  • Severe coagulopathy disorder or the use of anticoagulants.
  • Diagnosis of contralateral phrenic nerve palsy or severe Chronic Obstructive
  • Pulmonary Disease ().
  • History of chronic opioid use or neuropathic pain.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    Active Comparator: Intrafascial Injection Group

    In this group, interscalene anatomical structures and the phrenic nerve will be visualized under ultrasound guidance. A volume of 10 ml of local anesthetic solution will be injected directly into the brachial plexus sheath (intrafascial plane)

    Procedure: Ultrasound-Guided Intrafascial Injection (10 ml)

  • Experimental
    Experimental: Extrafascial Injection Group

    In this group, interscalene anatomical structures and the phrenic nerve will be visualized under ultrasound guidance. A volume of 10 ml of local anesthetic solution will be injected outside the brachial plexus nerve sheath (extrafascial plane)

    Procedure: Ultrasound-Guided Extrafascial Injection (10 ml)

Interventions

  • ProcedureUltrasound-Guided Intrafascial Injection (10 ml)

    Under ultrasound guidance, the interscalene brachial plexus and the phrenic nerve will be directly visualized on the anterior scalene muscle to be used as a landmark. A total of 10 ml of \[Local anesthetic medication name, e.g., 0.5% Bupivacaine\] solution will be injected strictly into the intrafascial plane, inside the nerve sheath

  • ProcedureUltrasound-Guided Extrafascial Injection (10 ml)

    Under ultrasound guidance, the interscalene brachial plexus and the phrenic nerve will be directly visualized on the anterior scalene muscle to be used as a landmark. A total of 10 ml of \[Local anesthetic medication name, e.g., 0.5% Bupivacaine\] solution will be injected strictly into the extrafascial plane, outside the nerve sheath

06

What researchers measure

Primary outcomes

  1. Incidence of Transient Hemidiaphragmatic Paralysis

    The incidence of transient diaphragmatic paralysis (phrenic nerve paresis) will be evaluated by measuring diaphragmatic excursion using diaphragm ultrasonography

    Time frame: At postoperative minute 0 and minute 30

Secondary outcomes

  1. Postoperative Pain Scores

    Postoperative pain severity will be assessed using the Numeric Rating Scale (NRS). The scale ranges from 0 to 10, where 0 represents 'no pain' and 10 represents 'worst imaginable pain'. Higher scores indicate a worse outcome (more severe pain)

    Time frame: Postoperative 1st, 3rd, 6th, 12th, and 24th hours

  2. Postoperative Total Opioid Consumption

    The amount of total opioid consumption will be recorded during the postoperative follow-up period

    Time frame: Postoperative 1st, 3rd, 6th, 12th, and 24th hours

  3. Incidence of Dyspnea

    The presence of shortness of breath (dyspnea) complaints from the patients will be evaluated and recorded

    Time frame: Up to 24 hours postoperatively

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Feb 2027, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2026
First posted
Nov 19, 2026
StartEst.
Oct 27, 2026
Primary completionEst.
Feb 26, 2027
CompletionEst.
Mar 27, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07948252
Responsible party
Baran Nas (Principal Investigator, Ankara Etlik City Hospital) — Principal investigator
First posted
Nov 19, 2026
Start date
Oct 27, 2026 (estimated)
Primary completion
Feb 26, 2027 (estimated)
Completion
Mar 27, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

BARAN NAS
Contact
hessam_nas@hotmail.com
00905547501481
Müge ÇAKIRCA
Contact
mugecakirca@gmail.com
00905054433177
BARAN NAS
principal investigator · Ankara Etlik City Hospital (Ankara Etlik Sehir Hastanesi)
MÜGE ÇAKIRCA
principal investigator · Ankara Etlik City Hospital (Ankara Etlik Sehir Hastanesi)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion